Physician profile
Oanh Lauring
NPI 1952355190
$762,605.77
in general payments reported to CMS, 2019-2025
47 companies · $270K in 2025
The $270K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $55K · 2021: $33K · 2022: $77K · 2023: $120K · 2024: $140K · 2025: $270K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $391K · Consulting Fee: $71K · Travel and Lodging: $36K · Food and Beverage: $31K · Education: $633 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $391,349.50 |
| Consulting Fee | $70,504.00 |
| Travel and Lodging | $35,676.27 |
| Food and Beverage | $31,329.29 |
| Education | $633.13 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $264,616.99 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Abbvie INC. | $210,055.93 | 2019-2025 | |
| Ucb, INC. | $83,550.65 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $46,264.56 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40,427.79 | 2022-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $32,953.52 | 2021-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $19,687.19 | 2019-2025 | |
| Dermavant Sciences, INC. | $17,037.91 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $10,953.07 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $9,914.42 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $8,472.11 | 2019-2025 | |
| Genzyme Corporation | $7,010.64 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $4,003.59 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,446.26 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Biotech, INC. | $1,323.08 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oanh Lauring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.